To assess the ability and specificity of MIL-38-CD3 to induce T cell killing of GPC-1-expressing prostate tumour cells, we chose two clinically relevant prostate cancer cell lines for assessment of T cell killing. Here, GPC1 is linked to prostate carcinoma.